{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:29:31Z","timestamp":1793694571880,"version":"4.5.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Hubei Province Natural Science Foundation","doi-asserted-by":"publisher","award":["2024AFD164"],"award-info":[{"award-number":["2024AFD164"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Hubei Province Natural Science Foundation","doi-asserted-by":"publisher","award":["2024AFD181"],"award-info":[{"award-number":["2024AFD181"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032579","name":"Beijing Medical Award Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.phrs.2026.109654","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:47:18Z","timestamp":1790869638000},"page":"109654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Activation of the EPO\u2013EPOR axis enhances dopamine agonist sensitivity through mitochondrial STAT5A\u2013mediated suppression of mtDNA transcription in prolactinomas"],"prefix":"10.1016","volume":"233","author":[{"given":"Xiang","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linpeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-sheng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuefeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.109654_bib1","first-page":"24","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019","author":"Ostrom","year":"2022","journal-title":"Neuro-oncology"},{"key":"10.1016\/j.phrs.2026.109654_bib2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41574-023-00883-8","article-title":"Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification","volume":"19","author":"Ho","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.phrs.2026.109654_bib3","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/jama.2023.5444","article-title":"Diagnosis and management of pituitary adenomas: a review","volume":"329","author":"Tritos","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2026.109654_bib4","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.phrs.2026.109654_bib5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1159\/000517356","article-title":"MicroRNAs in dopamine agonist-resistant prolactinoma","volume":"112","author":"Wan","year":"2022","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.phrs.2026.109654_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000497746","article-title":"Epidemiology and management challenges in prolactinomas","volume":"109","author":"Vroonen","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.phrs.2026.109654_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000495775","article-title":"Management of dopamine agonist-resistant prolactinoma","volume":"109","author":"Maiter","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.phrs.2026.109654_bib8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-12-0236","article-title":"Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients","volume":"167","author":"Vroonen","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.phrs.2026.109654_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11102-024-01493-x","article-title":"Exploring sex-specific hematological changes and their impact on quality of life in patients with prolactinoma","volume":"28","author":"Detomas","year":"2025","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.phrs.2026.109654_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ndt\/14.suppl_2.22","article-title":"The molecular biology of erythropoietin","volume":"14","author":"Lacombe","year":"1999","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.phrs.2026.109654_bib11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3389\/fimmu.2014.00563","article-title":"Erythropoietin and cancer: the unintended consequences of anemia correction","volume":"5","author":"Debeljak","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.109654_bib12","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-10-2577","article-title":"The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression","volume":"17","author":"Hedley","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.109654_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1756-8722-6-65","article-title":"Erythropoietin is a JAK2 and ERK1\/2 effector that can promote renal tumor cell proliferation under hypoxic conditions","volume":"6","author":"Miyake","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2026.109654_bib14","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ccell.2015.09.008","article-title":"Erythropoietin stimulates tumor growth via EphB4","volume":"28","author":"Pradeep","year":"2015","journal-title":"Cancer Cell."},{"key":"10.1016\/j.phrs.2026.109654_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-016-0306-x","article-title":"Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro","volume":"9","author":"V\u00e5tsveen","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2026.109654_bib16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.7150\/thno.11304","article-title":"Erythropoietin improves the accumulation and therapeutic effects of carboplatin by enhancing tumor vascularization and perfusion","volume":"5","author":"Doleschel","year":"2015","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2026.109654_bib17","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3892\/ijo.2011.1261","article-title":"Erythropoietin promotes the growth of pituitary adenomas by enhancing angiogenesis","volume":"40","author":"Yang","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.phrs.2026.109654_bib18","first-page":"22","article-title":"STAT5 as a key protein of erythropoietin signalization","author":"T\u00f3thov\u00e1","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.109654_bib19","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41419-021-03908-0","article-title":"Mitochondrial STAT5A promotes metabolic remodeling and the Warburg effect by inactivating the pyruvate dehydrogenase complex","volume":"12","author":"Zhang","year":"2021","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.phrs.2026.109654_bib20","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.bbrc.2020.04.152","article-title":"Signal transducer and activator of transcription 5a (STAT5a) represses mitochondrial gene expression through direct binding to mitochondrial DNA","volume":"527","author":"Chueh","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2026.109654_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adw9952","article-title":"Mitochondrial ROS drive foam cell formation via STAT5 signaling in atherosclerosis","volume":"11","author":"Boccuni","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.phrs.2026.109654_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2026.104077","article-title":"p300-mediated histone H3K18 lactylation promotes mitochondrial ROS accumulation via mitophagy inhibition to potentiate dopamine agonists efficacy in prolactinomas","volume":"91","author":"Li","year":"2026","journal-title":"Redox Biol."},{"key":"10.1016\/j.phrs.2026.109654_bib23","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1111\/bph.15504","article-title":"Exploiting D(2) receptor beta-arrestin2-biased signalling to suppress tumour growth of pituitary adenomas","volume":"178","author":"Tan","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.109654_bib24","article-title":"Androgen receptor mediates dopamine agonist resistance by regulating intracellular reactive oxygen species in prolactin-secreting pituitary adenoma","author":"Xu","year":"2024","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.phrs.2026.109654_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101056","article-title":"Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs","volume":"73","author":"Cheng","year":"2024","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.phrs.2026.109654_bib26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.kint.2025.06.005","article-title":"Executive summary of the KDIGO 2026 clinical practice guideline for the management of anemia in chronic kidney disease (CKD)","volume":"109","author":"Babitt","year":"2026","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2026.109654_bib27","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1346390","article-title":"Epobis is a nonerythropoietic and neuroprotective agonist of the erythropoietin receptor with anti-inflammatory and memory enhancing effects","volume":"2016","author":"Dmytriyeva","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.phrs.2026.109654_bib28","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1471-4159.2012.07751.x","article-title":"A new agonist of the erythropoietin receptor, Epobis, induces neurite outgrowth and promotes neuronal survival","volume":"121","author":"Pankratova","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.phrs.2026.109654_bib29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41392-025-02311-x","article-title":"Mitochondrial metabolism and cancer therapeutic innovation","volume":"10","author":"Du","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2026.109654_bib30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.trecan.2024.09.010","article-title":"Mitochondrial DNA damage, repair, and replacement in cancer","volume":"11","author":"Vodicka","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.phrs.2026.109654_bib31","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1530\/EJE-14-0990","article-title":"Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth","volume":"172","author":"Delgrange","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.phrs.2026.109654_bib32","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3171\/2010.11.JNS101369","article-title":"Dopamine agonist-resistant prolactinomas","volume":"114","author":"Oh","year":"2011","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.phrs.2026.109654_bib33","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/gerona\/glt154","article-title":"Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin\/hemoglobin set point","volume":"69","author":"Bachman","year":"2013","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"10.1016\/j.phrs.2026.109654_bib34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/02698811241295379","article-title":"Repurposing of erythropoietin as a neuroprotective agent against methotrexate-induced neurotoxicity in rats","volume":"39","author":"Sabry","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.phrs.2026.109654_bib35","article-title":"Subchronic intranasal administration of NeuroEPO reduces long-term consequences of severe traumatic brain injury in male rats","volume":"14","author":"L\u00f3pez-Preza","year":"2025","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.phrs.2026.109654_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115439","article-title":"Cyclic helix B peptide alleviates liver fibrosis via attenuating ROS-mediated pyroptosis","volume":"165","author":"Yuan","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phrs.2026.109654_bib37","first-page":"15","article-title":"Non-erythropoietic EPO (EPO-R76E) protects RPE cells from ferroptosis by modulating the labile iron pool and NRF2-GPX4 axis","author":"Gopi","year":"2026","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.phrs.2026.109654_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2026.119114","article-title":"MLPH-mediated activation of dermal papilla IGF-1 signaling drives human hair shaft elongation and anagen induction","volume":"196","author":"Kwack","year":"2026","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2026.109654_bib39","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4103\/1673-5374.353496","article-title":"Erythropoietin inhibits ferroptosis and ameliorates neurological function after spinal cord injury","volume":"18","author":"Kang","year":"2023","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.phrs.2026.109654_bib40","article-title":"Immuno-metabolic reprogramming by EPO delivery system accelerates achilles tendon regeneration via macrophage polarization and mitochondrial rescue","volume":"15","author":"Liu","year":"2026","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.phrs.2026.109654_bib41","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3892\/ijmm.2020.4784","article-title":"Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5\/cyclin D1 and STAT5\/Bcl\u2011xL signaling pathways","volume":"47","author":"Xiao","year":"2020","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.phrs.2026.109654_bib42","article-title":"The activation of p300 enhances the sensitivity of pituitary adenomas to dopamine agonist treatment by regulating the transcription of DRD2","volume":"25","author":"Li","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.109654_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2023.102883","article-title":"Prolactinomas resistant to dopamine agonists: pathophysiology and treatment","volume":"54","author":"Shimon","year":"2023","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.phrs.2026.109654_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011247","article-title":"Molecular pathways in prolactinomas: translational and therapeutic implications","volume":"22","author":"Biagetti","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.109654_bib45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/neuonc\/noad148","article-title":"A disintegrin and metalloproteinase 22 activates integrin beta1 through its disintegrin domain to promote the progression of pituitary adenoma","volume":"26","author":"Xing","year":"2024","journal-title":"Neuro Oncol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826015690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826015690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:08:29Z","timestamp":1793693309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826015690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":45,"alternative-id":["S1043661826015690"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.109654","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activation of the EPO\u2013EPOR axis enhances dopamine agonist sensitivity through mitochondrial STAT5A\u2013mediated suppression of mtDNA transcription in prolactinomas","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.109654","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109654"}}